Latest Breaking News On - Interim chief medical - Page 1 : comparemela.com

Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Vir Biotechnology, Inc.: Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

- Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial - - Conference call scheduled for June 5, 2024, at 6:00 a.m. ET 12:00 p.m. CEST - Vir Biotechnology

Faron's Financial Statement Release January 1 to December

TURKU, Finland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) Faron Pharmaceuticals Ltd. (

Faron's Financial Statement Release January 1 to December 31, 2023 -March 13, 2024 at 03:01 am EDT

TURKU, Finland and BOSTON, March 13, 2024 Faron Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies,.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript

Fulcrum Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.44.